Hormonal
Semaglutide (2.4 mg once-weekly subcutaneous) significantly reduces body weight in adults with obesity or overweight with comorbidities compared to placebo.
For adults with obesity or overweight who have at least one weight-related health issue (like high blood pressure or cholesterol), a once-weekly injection of semaglutide (2.4 mg) combined with lifestyle changes can lead to significant, sustained weight loss (averaging nearly 15% of body weight in trials). While gastrointestinal side effects like nausea are common, they often subside, and starting with a lower dose can help your body adjust.
At week 68, the mean body weight change was highly significant in the semaglutide group vs. the placebo group (-14.9 vs. -2.4%; ETD, -12.4%; P<0.001).
Why this rating
Based on Phase III randomized, double-blind, placebo-controlled trials (STEP program).
Source
Future perspectives in diabesity treatment: Semaglutide, a glucagon‑like peptide 1 receptor agonist (Review)
Mariana Cornelia Tilinca et al. · Experimental and Therapeutic Medicine · 2021
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →